U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07113496) titled 'RN1201injection for Relapsed/Refractory B-cell Hematologic Malignancies' on July 24.
Brief Summary: This single-arm, dose-escalation exploratory trial evaluates the safety and efficacy of Allogeneic CAR-T (UCAR-T) cell therapy in patients with relapsed or refractory B-cell hematologic malignancies, including those with minimal residual disease (MRD). Eligible patients will receive lymphodepletion followed by a single infusion of UCAR-T cells, either post-transplant or without transplantation depending on disease status. The trial assesses overall response and disease control rates, treatment-emergent adverse events, and in vivo behav...